No Need To Change Regs To Suit Nanotech Drugs: FDA Official

Law360, New York (August 9, 2012, 7:36 PM EDT) -- A U.S. Food and Drug Administration official said Thursday she believed the agency could adequately evaluate drugs containing nanotechnology under the current regulatory framework, though she emphasized that more government research was needed in the area.

“Our regulatory system is quite adequate, and we do not feel from previous evaluations that there are any deficiencies,” Nakissa Sadrieh, the associate director for research policy implementation at the FDA's Center for Drug Evaluation and Research, told an advisory panel examining the agency's handling of information from submissions for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.